共 25 条
- [22] Rationale, design and method of olmesartan and calcium antagonists randomized (OSCAR) study: The study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients JOURNAL OF HYPERTENSION, 2008, 26 : S511 - S511
- [23] Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160) HYPERTENSION RESEARCH, 2009, 32 (07) : 575 - 580
- [24] Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160) Hypertension Research, 2009, 32 : 575 - 580
- [25] Starke Blutdrucksenkung durch hochdosierte Kombinationstherapie von 160 mg Valsartan und 25 mg HCT in der alltäglichen Behandlungspraxis bei Patienten mit erhöhtem kardiovaskulären RisikoErgebnisse der MACHT-II-BeobachtungsstudieIntensive Blood Pressure Reduction in Patients with Increased Cardiovascular Risk with High-Dose Combination Therapy of 160 mg Valsartan plus 25 mg Hydrochlorothiazide. Results of the MACHT II Observational Study Herz Kardiovaskuläre Erkrankungen, 2007, 32 (5) : 419 - 425